CONNEQT Arterial Health Assessment - Clinically Proven. Research Backed.
Comprehensive arterial health analysis that reveals hidden risks linked to heart disease, stroke, and vascular aging.
The CONNEQT Arterial Assessment provides advanced insights into vascular health by measuring key biomarkers like arterial stiffness and central blood pressure. This technology enables early detection of cardiovascular risks and supports proactive heart health management.
Begin the process by ordering your Arterial Health Assessment Kit.
We'll ask a few simple questions to ensure you qualify. Once approved, the Arterial Health Assessment Kit, including the Pulse biometric monitor (yours to keep), will be shipped directly to you.
The Pulse is a clinical-grade health monitor that goes beyond standard blood pressure cuffs by measuring advanced cardiovascular biomarkers like central blood pressure, arterial stiffness, and heart stress. These insights reveal the true state of your heart and arteries—long before symptoms appear—empowering you to take action early, train smarter, and live longer.
Cardiology Report
After completing a series of readings with the Pulse, you’ll receive two personalized cardiology reports—each offering a detailed analysis of your arterial health and cardiovascular function.
- The first report is generated after your initial set of readings.
-
The second (more comprehensive) report is delivered once enough data is collected to reveal meaningful trends in your arterial health over time.
These reports are powerful tools—for both your personal health journey and your physician’s clinical decision-making.
You can also access On-Demand spot-check reports anytime via the CONNEQT App for quick, real-time insights.
2. For your physician
Start a data-driven conversation with your doctor. Your report includes:
- A clear explanation of arterial stiffness, its measurement, and its impact on cardiovascular health.
- A comprehensive summary of key vascular biomarkers, clinical interpretation, and treatment considerations to help guide medical decisions.
CONNEQT®App
Once you are set up and receiving reports you can gain ongoing real-time insights into your arterial health and understand how your cardiovascular system is functioning like never before.
The CONNEQT App translates complex vascular data into actionable recommendations, helping you track trends, optimize heart health, and make informed lifestyle choices. Follow Guided Programs for tailored steps to improve your arterial health and overall well-being.
Research-Backed Health Insights
Traditional blood pressure readings only tell part of the story. The Pulse arterial health monitor uses Pulse Wave Analysis (PWA) to measure key vascular biomarkers that predict cardiovascular (CV) risk before symptoms appear.
By tracking these biomarkers, the CONNEQT Pulse helps detect hidden risks, optimize heart health, and empower better cardiovascular decisions.
Results & Clinical Interpretation of CONNEQT Arterial Health Biomarkers
| Measurement | Central Blood Pressure | Central Pulse Pressure | Pulse Pressure Amplification | Augmentation Pressure | Augmentation Index |
|---|---|---|---|---|---|
| Threshold | >130 mmHg | >50 mmHg | <130% | Each 10 mmHg increase in AP | Each 10 % increase in Alx |
| Risk of Cardiovascular Events | 3 times increased risk of cardiovascular events* | 2-3 times increased risk of cardiovascular events* | 2-3 times increased risk of cardiovascular events* | Increases the risk of cardiovascular events* by 30% | Increases the risk of cardiovascular events* by 35-40% |
*Cardiovascular events are defined as a myocardial infarction, coronary revascularization, stroke, heart failure, or cardiovascular mortality.
A 4-mmHg reduction in central pressure can lower cardiovascular risk by 20%. Reductions in arterial stiffness have been shown with ACE-inhibitors, calcium channel blockers, statins, PCSK9 inhibitors, and SGLT2 inhibitors.
Our SphygmoCor® Technology by the Numbers
Top 20
All “Top 20 Hospitals” use SphygmoCor technology to measure central blood pressure (cBP)
2,700+
SphygmoCor technology has supported studies that have resulted in over 2,700 peer-reviewed publications.
8/10
8 out of top 10 Pharma companies have used SphygmoCor technology in their clinical trials
11,000
Over 11,000 patients have been tested with SphygmoCor technology in pharmaceutical trials
Hypertension Specialist
“SphygmoCor has transformed the way we treat hypertension. By using central aortic pressure readings, we can target treatments more precisely, improving patient outcomes without adding complexity to our workflow”
Dr. Mark C. Houston, MD
Director, Hypertension Institute and Vascular Biology
Medical Director of Division of Human Nutrition
Medical Director of Clinical Research
ASH Specialist in Clinical Hypertension (FASH)
Vanderbilt University School of Medicine Associate Clinical Professor of Medicine (1990-2012)
Cardiologist – Heart Failure/Pulmonary Hypertension Specialist
“CONNEQT’s Pulse device has the potential to significantly improve treatment decisions by physicians and the health outcomes of patients through the use of advanced blood pressure and vascular health technologies.”
Dr. Hunter Champion, MD, PhD, FAHA
Southeastern Cardiology Associates
CONNEQT SphygmoCor® Technology in Clinical Practice
Dr Hunter Champion MD, PhD, FAHA from Southeastern Cardiology Associates talks about advanced arterial health monitoring using SphygmoCor arterial biomarkers.
The Gold Standard in Arterial Health—Trusted Worldwide
Powered by SphygmoCor®
CONNEQT Pulse is powered by our patented SphygmoCor® technology, the gold standard in arterial health assessment, used by leading cardiovascular researchers, pharmaceutical companies, and healthcare institutions worldwide.
- Used by Mayo Clinic, Cleveland Clinic, Weill Cornell, and top research hospitals.
- Integrated into clinical trials for major pharmaceutical companies.
- Validated by over 2700 peer reviewed research papers on arterial health and cardiovascular risk assessment.
*An itemized receipt is provided for FSA/HSA reimbursement.